Satsuma Pharmaceuticals (STSA) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free STSA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSatsuma City High Schoolusnews.com - August 30 at 5:25 PMJapanese pharma acquires its crash-strapped Durham spin-outbizjournals.com - June 9 at 3:18 PMJapanese pharma acquires its Durham spin-outbizjournals.com - June 8 at 4:49 PMmarketbeat.com - June 8 at 6:00 AMSatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migrainefinance.yahoo.com - May 18 at 8:06 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRAmarketwatch.com - May 3 at 5:56 PMShareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nipponbenzinga.com - May 1 at 8:34 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRAmarketwatch.com - April 25 at 4:05 PMSTSA Satsuma Pharmaceuticals, Inc.seekingalpha.com - April 22 at 6:34 PMSatsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meetingfinance.yahoo.com - April 21 at 10:22 AMAfter Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upsidemsn.com - April 19 at 12:39 AMSatsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSAmarketwatch.com - April 18 at 1:38 AMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. Buyoutbenzinga.com - April 17 at 3:37 PMPeninsula company bets big part of potential $221M sale on future of migraine drugbizjournals.com - April 17 at 3:37 PMSatsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedicalmarkets.businessinsider.com - April 17 at 10:36 AMSatsuma Skyrockets after Acquisition by Shin Nipponmsn.com - April 17 at 10:36 AMWhy Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?investorplace.com - April 17 at 9:09 AMSNBL to Acquire Satsuma Pharmaceuticalsfinance.yahoo.com - April 16 at 11:18 PMH.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)markets.businessinsider.com - March 30 at 10:15 AMWe're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Ratefinance.yahoo.com - March 30 at 10:15 AMMigraine drug maker seeks FDA approval and a partner as it cuts jobsbizjournals.com - March 29 at 1:49 PMSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlightsfinance.yahoo.com - March 28 at 6:05 PM8-K: Satsuma Pharmaceuticals, Inc.marketwatch.com - February 18 at 2:42 PMSTSA.Oreuters.com - February 7 at 9:22 AMSatsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 2 at 11:19 AMDespite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For Approvalfinance.yahoo.com - December 28 at 7:44 AMSatsuma Pharmaceuticals Provides STS101 Development Program and Corporate Updatefinance.yahoo.com - December 20 at 1:48 PMMizuho Securities Reaffirms Their Hold Rating on Satsuma Pharmaceuticals (STSA)markets.businessinsider.com - December 18 at 8:26 PMAs Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) gains 14%, insiders who bought last year may be wishing they had bet higherfinance.yahoo.com - November 30 at 11:39 AM10% Owner of Satsuma Pharmaceuticals Makes $106K Buybenzinga.com - November 23 at 2:37 PMSatsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conferencefinance.yahoo.com - November 23 at 2:37 PMSatsuma Pharma Shares Nosedives After Disappointing Data From Migraine Studyfinance.yahoo.com - November 22 at 5:14 AMSatsuma Pharmaceuticals (NASDAQ:STSA) Price Target Lowered to $3.00 at LADENBURG THALM/SH SHmarketbeat.com - November 20 at 3:36 AM10% Owner of Satsuma Pharmaceuticals Purchased $4.39M In Stockbenzinga.com - November 17 at 12:12 PMSatsuma Pharmaceuticals 10% Owner Trades Company's Stockbenzinga.com - November 17 at 12:12 PMHC Wainwright & Co. Maintains Buy Rating for Satsuma Pharmaceuticals: Here's What You Need To Knowbenzinga.com - November 15 at 12:55 PMPeninsula drug maker's stock blows up after 2nd nasal migraine drug flopbizjournals.com - November 14 at 11:11 PMWhy Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?investorplace.com - November 14 at 1:02 PMSatsuma Pharma's migraine drug fails late-stage study, shares crashreuters.com - November 14 at 10:52 AMSatsuma Pharma's migraine drug fails in late-stage studyreuters.com - November 14 at 10:52 AMSatsuma crashes 80% as migraine therapy STS101 fails phase 3 trialseekingalpha.com - November 14 at 10:52 AMSatsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migrainefinance.yahoo.com - November 14 at 10:52 AMMizuho Securities Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)markets.businessinsider.com - November 6 at 7:55 PMSatsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlightsfinance.yahoo.com - November 4 at 12:47 PMShort Interest in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Increases By 15.0%marketbeat.com - October 29 at 7:46 PMHere's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situationfinance.yahoo.com - October 20 at 5:16 PMSatsuma Pharmaceuticals, Inc. (STSA)finance.yahoo.com - October 20 at 9:35 AMSatsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Sees Significant Increase in Short Interestmarketbeat.com - October 14 at 2:58 PMBenzinga's Top Ratings Upgrades, Downgrades For October 10, 2022msn.com - October 10 at 12:24 PMSatsuma stock surges 11% after SVB upgrades on potential positive data for migraine therapy STS-101seekingalpha.com - October 10 at 12:24 PM Get Satsuma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. STSA Media Mentions By Week STSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STSA News Sentiment▼0.000.42▲Average Medical News Sentiment STSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STSA Articles This Week▼00▲STSA Articles Average Week Get Satsuma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Xilio Therapeutics News Today BriaCell Therapeutics News Today Unicycive Therapeutics News Today Fortress Biotech News Today Ocuphire Pharma News Today Cara Therapeutics News Today JanOne News Today ProMIS Neurosciences News Today Marker Therapeutics News Today Viracta Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STSA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarningsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satsuma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
